Demonstration of the first known 1:2 host-guest encapsulation of a platinum anticancer complex within a macrocycle

被引:0
作者
Yvonne E. Moussa
Natarajan S. Venkataramanan
Nial J. Wheate
机构
[1] The University of Sydney,Faculty of Medicine and Health, Sydney Pharmacy School
[2] SASTRA Deemed University,School of Chemistry and Biotechnology
来源
Journal of Inclusion Phenomena and Macrocyclic Chemistry | 2020年 / 96卷
关键词
Cancer; Oxaliplatin; Host-guest; Drug delivery; Macrocycle; Calixarene;
D O I
暂无
中图分类号
学科分类号
摘要
This study examined the ability of the para-sulfonatocalix[8]arene (sCX[8]) macrocycle to encapsulate [Pt(H2O)2(R,R-dach)]2+, the active aquated component of oxaliplatin. Both the free 1R,2R-diaminocyclohexane (dach) ligand and [Pt(H2O)2(R,R-dach)]2+ formed host-guest complexes with sCX[8], as indicated by 1H nuclear magnetic resonance (NMR) spectroscopy and molecular modelling. This interaction uniquely occurred in a 1:2 host-guest stoichiometric ratio, such that one platinum molecule was bound at each of the two sCX[8] pseudo-cavities. The 1H NMR data showed this binding to be predominantly stabilised by hydrophobic effects, hydrogen bonds and electrostatic interactions, the latter of which were evidenced by the lack of host-guest complex formation for the uncharged [PtCl2(R,R-dach)] derivative. Contrastingly, molecular modelling results indicated that host-guest complex formation was predominantly due to hydrogen bonds and electrostatic interactions at the surface of the macrocycle, such that the dach groups of [Pt(H2O)2(R,R-dach)]2+ were projecting away from, and not bound through hydrophobic effects with, the pseudo-cavities of sCX[8]. Guanosine 5′-monophosphate binding studies demonstrated that complexation with the macrocycle did not affect the ability of [Pt(H2O)2(R,R-dach)]2+ to interact with its target, but rather, it was capable of doing so while still bound to sCX[8]. In total, these findings point to the potential role of sCX[8] as a delivery vehicle for other charged platinum complexes.
引用
收藏
页码:145 / 154
页数:9
相关论文
共 171 条
[1]  
Dong W(2005)Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 307-320
[2]  
Stephen JL(2015)The state-of-play and future of platinum drugs Endocr. Relat. Cancer 22 219-233
[3]  
Apps MG(2019)Platinum drugs in the Australian cancer chemotherapy healthcare setting: is it worthwhile for chemists to continue to develop platinums? Inorg. Chim. Acta 492 177-181
[4]  
Choi EHY(2014)Understanding and improving platinum anticancer drugs—phenanthriplatin Anticancer Res. 34 471-476
[5]  
Wheate NJ(2017)Drug delivery strategies for platinum-based chemotherapy ACS Nano 11 8560-8578
[6]  
Um IS(2016)Targeted drug delivery system for platinum-based anticancer drugs Mini.-Rev. Med. Chem. 16 872-891
[7]  
Armstrong-Gordon E(2012)Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery Pharm. Res. 29 2456-2467
[8]  
Moussa YE(2009)Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs J. Inorg. Biochem. 103 373-380
[9]  
Gnjidic D(2017)Design, properties and recent application of macrocycles in medicinal chemistry Chimia 71 678-702
[10]  
Wheate NJ(2015)Macrocycles: lessons from the distant past, recent developments, and future directions Chem. Sci. 6 30-49